CBM Cambrex Corporation

Cambrex to Announce Third Quarter 2018 Financial Results on November 8, 2018

Cambrex to Announce Third Quarter 2018 Financial Results on November 8, 2018

EAST RUTHERFORD, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that third quarter 2018 financial results will be released on Thursday, November 8, 2018 before the market opens.

The Company will host a conference call to discuss the financial results.

 Third Quarter 2018 Earnings Conference Call
  
When:Thursday, November 8, 2018 at 8:30 a.m. Eastern Time
  
Dial-in:1-877-830-2649 for U.S.
  for International
 Passcode:  3109072
  
Dial-in Replay:1-888-203-1112 for U.S.
  for International
 Passcode:  3109072
 Available through Thursday, November 15, 2018
  
Webcast: 

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients (APIs), finished dosage forms, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing.  For more information, please visit .

Contact:  

Stephanie LaFiura                                                                              

Investor Relations Associate                                                             

Tel: 201-804-3037                                                      

Email:       

EN
05/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cambrex Corporation

Moody's Ratings downgrades Cambrex's CFR to B3, outlook remains negati...

Moody's Ratings (Moody's) downgraded the ratings of Cambrex Corporation's ("Cambrex") including the Corporate Family Rating (CFR) to B3 from B2 and the Probability of Default Rating (PDR) to B3-PD from B2-PD. Concurrently, Moody's downgraded the rating of the backed senior secured first lien bank fa...

Cambrex Corporation: Update to credit analysis following change of out...

Our credit view of this issuer reflects its high financial leverage and aggressive M&A posture offset by its high quality manufacturing facilities, and one of only a few CDMO’s of scale.

Moody's changes Cambrex's outlook to negative; affirms B2 CFR

Moody's Investors Service ("Moody's") today affirmed Cambrex Corporation's ("Cambrex") B2 corporate family rating (CFR) and B2-PD probability of default rating (PDR). Concurrently, Moody's affirmed the B2 rating of the backed senior secured first lien bank facility. The outlook was changed to negati...

Cambrex Corporation: Update to credit analysis

Cambrex' credit profile reflects its high financial leverage and concentration in small molecules offset by its capabilities as a fully integrated CDMO and strong demand for its services.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch